RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboFirst posted here in September 2022 - when few knew about Summitt Therapeutics and SMMT was trading at US$1.29 per share ..... ONCY pelareorep + CD3 bispecific antibody true-killer combo.... a true tumor-killer combo that would not be effective without each other. Both bispecific T-cell engagers and oncolytic viruses are promising cancer therapies, but the new research demonstrates that combining the two approaches could work even better. The researchers first administered oncolytic reovirus to both syngeneic murine and humanized tumor models, then injected the CD3ε-bispecific antibodies. The combined treatment induced strong tumor regression and prolonged survival compared to each treatment option individually.
Preconditioning the tumor microenvironment with oncolytic reovirus resulted in the activation of immunologically cold tumors, explained the researchers. This in turn led to more successful engagement of bispecific antibodies, causing tumor cell death.
https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/